Amyotrophic Lateral Sclerosis Clinical Trial
Official title:
Repetitive Transcranial Magnetic Stimulation in Amyotrophic Lateral Sclerosis
The investigators' preliminary studies demonstrated that repetitive transcranial magnetic stimulation (rTMS) of the brain may determine a slight slowing in the rate of disease progression in ALS patients (Di Lazzaro et al 2004, 2006). The aim of this study is to investigate whether rTMS of the motor cortex performed over a long period of time (12 months) in a group of patients with ALS, can have a more pronounced beneficial effect. The investigators will compare the disease progression in two groups of patients: the first group of patients will be treated with real rTMS (one week daily treatment every month) and the second group of patients will be treated with sham (placebo) rTMS.
Eligible patients should have a diagnosis of definite ALS according to the El Escorial
revised criteria with clear clinical upper and lower motor neuron signs. Twenty patients
with definite ALS will be enrolled and will be allocated to the treatment: 10 active and 10
sham stimulation. Patients will be randomly allocated by one of the investigators not
involved in follow-up evaluations and data analysis. Stratified block randomisation will be
performed such that the two treatment groups will be evenly balanced for disease severity,
as evaluated with the revised ALS functional rating scale (ALSFRS-R), and duration. The
patients and the neurologists assessing the outcomes will be blinded to group assignment.
Outcome measures Patients will be evaluated at the beginning of the treatment and every
month until the end of the study at 1 year. At each visit, patients will be evaluated using
the ALSFRS-R and manual muscle testing (MMT). MMT testing will be performed by means of the
Medical Research Council (MRC) Scale. To obtain an estimate of the overall limb muscle
strength we will calculate a MRC compound score by adding the MRC scores of eight upper limb
muscles and five lower limb muscles for each side and dividing the sum by the number of
muscles tested (26 muscles). We will test the following muscles: biceps brachii, deltoid,
triceps brachii, extensor carpi radialis , extensor digitorum communis, abductor digiti
minimi, abductor pollicis brevis, opponens pollicis, iliopsoas, rectus femoris, tibialis
anterior, extensor hallucis longus, gastrocnemius.
The primary outcome measure will be the rate of decline of ALSFRS-R scores. Secondary
outcome measure will be the rate of decline in MMT.
Transcranial brain stimulation Central motor conduction time for the first dorsal
interosseous muscle will calculated by subtracting the peripheral conduction time, from
spinal cord to muscles, from the latency of responses evoked by cortical stimulation at the
maximum stimulator output during voluntary contraction at about 20% of maximum.
Repetitive TMS will be applied over the hand motor area using a MagPro (Medtronic A/S
Denmark) stimulator and a figure of eight-shaped coil.
Active rTMS will be performed using the cTBS pattern in which 3 pulses of stimulation are
given at 50Hz, repeated every 200 ms for a total of 600 pulses. We will use a butterfly coil
(MCF-B-65) with the handle pointed posteriorly and approximately perpendicular to the
central sulcus. The initial direction of the current induced in the brain will be
posterior-anterior. The stimulation intensity will be 80 % of the active motor threshold
(AMT), defined as the minimum single pulse intensity required to produce a motor evoked
potential greater than 200 uV on more than five out of ten trials from the contracted
contralateral first interosseous muscle. This protocol leads to pronounced and prolonged
suppression of cortical excitability that reaches a maximum about 5-10 min after the end of
the stimulation.
Sham rTMS will be performed using the same stimulator connected to the placebo butterfly
coil MCF-P-B-65 which has no stimulating effect on the cortex but produces similar auditory
and tactile sensations as the active coil. The site of stimulation and the number of stimuli
will be identical to those used for the active magnetic rTMS.
Repetitive TMS will be performed bilaterally. The order of stimulation of the two
hemispheres will be randomized. The stimulation of the two hemispheres will be performed
sequentially at an interval of one minute. The motor cortex of each side will be stimulated
for five consecutive days every month for twelve consecutive months. In the patients with
absent first dorsal interosseous motor evoked potentials after stimulation of one
hemisphere, the repetitive stimulation will be performed at the same intensity used for the
opposite hemisphere.
Statistical analysis Statistical analysis will be performed using a two-factor (TIME and
TREATMENT) repeated measures analysis of variance.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04428775 -
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
|
Phase 2 | |
Recruiting |
NCT04998305 -
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
|
Phase 1/Phase 2 | |
Recruiting |
NCT05951556 -
Telehealth Implementation of Brain-Computer Interface
|
N/A | |
Terminated |
NCT04579666 -
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Recruiting |
NCT04082832 -
CuATSM Compared With Placebo for Treatment of ALS/MND
|
Phase 2/Phase 3 | |
Completed |
NCT01925196 -
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
|
||
Completed |
NCT02496767 -
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
|
Phase 3 | |
Recruiting |
NCT04816227 -
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
|
||
Active, not recruiting |
NCT04494256 -
A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation
|
Phase 1/Phase 2 | |
Completed |
NCT03706391 -
Study of ALS Reversals 4: LifeTime Exposures
|
||
Recruiting |
NCT04882904 -
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
|
N/A | |
Completed |
NCT04557410 -
Open Label Study: Treatment of ALS Fatigue With PolyMVA
|
Phase 1 | |
Active, not recruiting |
NCT04948645 -
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
Not yet recruiting |
NCT04089696 -
Validation of the "ExSpiron©" in Patients With ALS
|
N/A | |
Not yet recruiting |
NCT04220190 -
RAPA-501 Therapy for ALS
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05860244 -
Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients
|
Phase 2 | |
Not yet recruiting |
NCT06450691 -
Modeling Amyotrophic Lateral Sclerosis With Fibroblasts
|
N/A | |
Recruiting |
NCT02917681 -
Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03067857 -
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT02874209 -
Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis
|
N/A |